MARKET

RNAZ

RNAZ

Transcode Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.900
-0.080
-2.68%
After Hours: 2.890 -0.01 -0.34% 18:55 07/29 EDT
OPEN
2.950
PREV CLOSE
2.980
HIGH
3.030
LOW
2.860
VOLUME
238.35K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
2.670
MARKET CAP
34.70M
P/E (TTM)
-10.4996
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 6d ago
61 Biggest Movers From Yesterday
Gainers
Benzinga · 07/22 09:01
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to purchase Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021.
Benzinga · 07/21 16:01
Chembio Diagnostics, NeuroMetrix leads healthcare gainers; NeuroBo Pharmaceuticals, Healthcare Services among major losers
Gainers: Chembio Diagnostics CEMI +195%, NeuroMetrix (NURO) +143%, TRxADE HEALTH MEDS +40%, TransCode Therapeutics (RNAZ) +24%, Cassava Sciences (SAVA) +20%.Losers: NeuroBo Pharmaceuticals (NRBO) -19%, Healthcare Services HCSG -11%, Lumos Pharma (LUMO) -12...
Seekingalpha · 07/21 15:01
54 Biggest Movers From Yesterday
Gainers
Benzinga · 07/20 09:05
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 07/19 16:31
30 Stocks Moving In Monday's Mid-Day Session
Gainers Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM.
Benzinga · 07/19 16:02
Freeline Therapeutics, Cytokinetics leads healthcare gainers; China SXT Pharmaceuticals, Atossa Therapeutics among major losers
Gainers: Freeline Therapeutics (FRLN) +88%, Cytokinetics CYTK +49%, NRx Pharmaceuticals NRXP +37%, Allied Healthcare Products (AHPI) +19%, Aethlon Medical (AEMD) +16%.Losers: China SXT Pharmaceuticals (SXTC) -21%, Atossa Therapeutics (ATOS) -15%, TransCode...
Seekingalpha · 07/19 15:00
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RNAZ. Analyze the recent business situations of Transcode Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Independent Director
Magda Marquet, PhD
Independent Director
Erik Manting, PhD
Co-Founder, Scientific Advisor
Anna Moore, PhD
Co-Founder and Vice President Drug Discovery
Zdravka Medarova, PhD
Vice President of Operations
Judy Carmody, PhD
Chief Scientist
Qiyong Peter Liu, PhD
Independent Director, Chairman of the Board of Directors
Philippe P. Calais, PhD
Vice President, Chief Financial Officer, Director
Thomas A. Fitzgerald, MBA
Co-Founder, President, Chief Executive Officer, Director
Robert Michael Dudley
No Data
About RNAZ
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Webull offers kinds of Transcode Therapeutics Inc stock information, including NASDAQ:RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.